Avita Medical (ASX:AVH) reported Friday a loss of $0.44 per diluted share in the fourth quarter of 2024, compared with a loss of $0.28 per diluted share in the same period in 2023.
Analysts polled by Visible Alpha also expected a loss of $0.44.
The dual-listed firm said the wider net loss was due to higher operating expenses and lower other income, net, partially offset by higher gross profit.
Total revenue in the quarter ended Dec. 31, 2024, came in at $18.4 million, compared with $14.2 million in the corresponding period in the prior year. Analysts polled by Visible Alpha expected $20.3 million.
The company said it expects its full-year 2025 commercial revenue to be in the range of $100 to $106 million, reflecting growth of approximately 55% to 65% over the full-year 2024.
The company's shares surged past 12% in recent Friday trade in Australia.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。